Clinical course of advanced non-small cell lung cancer (NSCLC) patients (pts) experiencing hypertension (HTN) during treatment (TX) with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) on E4599.

8042 Background: B is a monoclonal antibody that targets VEGF with demonstrated efficacy in combination with PC for the TX of advanced NSCLC. Administration of B is thought to decrease nitrous oxide synthesis and lead to HTN, one of the known toxicities associated with PCB on E4599. This side effect...

Full description

Bibliographic Details

Published in:	Journal of Clinical Oncology Vol. 27; pp. 8042 - 8043
Main Authors:	Dahlberg, S E, Sandler, A B, Brahmer, J R, Schiller, J H, Johnson, D H
Format:	Journal Article
Published:	American Society of Clinical Oncology 5/21/2009 Supplement Part 1 of 2
Online Access:	View this record in EBSCOhost